SG Americas Securities LLC Has $3.59 Million Stock Position in Kenvue Inc. (NYSE:KVUE)

SG Americas Securities LLC decreased its stake in Kenvue Inc. (NYSE:KVUE) by 45.8% in the first quarter, HoldingsChannel reports. The firm owned 149,704 shares of the company’s stock after selling 126,346 shares during the period. SG Americas Securities LLC’s holdings in Kenvue were worth $3,590,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Fulton Bank N.A. boosted its position in shares of Kenvue by 0.6% in the 1st quarter. Fulton Bank N.A. now owns 78,888 shares of the company’s stock valued at $1,892,000 after purchasing an additional 465 shares during the period. White Pine Capital LLC boosted its position in shares of Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company’s stock valued at $1,165,000 after purchasing an additional 542 shares during the period. Deseret Mutual Benefit Administrators boosted its position in shares of Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company’s stock valued at $54,000 after purchasing an additional 568 shares during the period. SRS Capital Advisors Inc. boosted its position in shares of Kenvue by 67.4% in the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company’s stock valued at $30,000 after purchasing an additional 571 shares during the period. Finally, Keystone Financial Group boosted its position in Kenvue by 4.8% during the 4th quarter. Keystone Financial Group now owns 12,736 shares of the company’s stock worth $272,000 after acquiring an additional 578 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Stock Down 2.7%

KVUE opened at $21.44 on Friday. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $25.17. The business has a 50-day moving average of $23.02 and a 200-day moving average of $22.52. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market capitalization of $41.14 billion, a PE ratio of 40.46, a price-to-earnings-growth ratio of 2.62 and a beta of 0.98.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.24 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.01. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. During the same period last year, the business earned $0.28 EPS. The business’s quarterly revenue was down 3.9% on a year-over-year basis. Equities research analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, May 28th. Stockholders of record on Wednesday, May 14th were paid a dividend of $0.205 per share. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.82%. The ex-dividend date was Wednesday, May 14th. Kenvue’s dividend payout ratio (DPR) is presently 149.09%.

Analysts Set New Price Targets

KVUE has been the subject of a number of research reports. Redburn Atlantic initiated coverage on Kenvue in a research report on Thursday, April 10th. They set a “neutral” rating and a $23.50 price objective for the company. Barclays raised their price objective on Kenvue from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Monday, May 12th. Piper Sandler raised their price objective on Kenvue from $24.00 to $27.00 and gave the stock an “overweight” rating in a research report on Monday, February 24th. Canaccord Genuity Group raised their price objective on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, March 5th. Finally, Evercore ISI initiated coverage on Kenvue in a research report on Monday, March 24th. They set an “in-line” rating and a $25.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $25.33.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.